• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

婴幼儿血管瘤:并发症、复发和不美观后遗症的风险因素。

Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae.

机构信息

Postgraduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.

Faculty of Medicine, Universidade Federal do Pampa, Uruguaiana, RS, Brazil.

出版信息

An Bras Dermatol. 2022 Jan-Feb;97(1):37-44. doi: 10.1016/j.abd.2021.05.009. Epub 2021 Nov 27.

DOI:10.1016/j.abd.2021.05.009
PMID:34848114
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8799848/
Abstract

BACKGROUND

Infantile hemangiomas (IH) occur in approximately 4% to 10% of the pediatric population. The identification of clinical subtypes and conditions that indicate increased risk for complications is essential for therapeutic success.

OBJECTIVES

To identify risk factors for complications, recurrence and unaesthetic sequelae.

METHODS

Retrospective cohort of patients with infantile hemangiomas undergoing follow-up at the Dermatology Service of Universidade Federal de Ciências da Saúde de Porto Alegre, between 2006 and 2018.

RESULTS

190 patients were included; 24% had some type of complication, ulceration being the most frequent, and 86% required treatment. On correlation, ulceration was statistically related to mixed IH (p = 0.004), segmental IH (p < 0.01) and location in the gluteal region (p = 0.001). The mean time of treatment with propranolol was 12.7 months. Patients with PHACES syndrome and segmental infantile hemangioma required longer treatment (p < 0.001 and p = 0.0407, respectively), as well as those who started treatment after five months of life (p < 0.0001). Recurrence occurred in 16.6% of the treated patients, all-female; 94% were located on the head and neck (mainly on the upper eyelid, cyrano, S3 segment, and with parotid involvement); 61% and 38.8% were of the mixed and deep subtypes, respectively. Approximately 1/3 of the patients had some unaesthetic sequelae.

STUDY LIMITATIONS

As this is a retrospective study, data and photos of some patients were lost.

CONCLUSIONS

Mixed and segmental hemangiomas are risk factors for ulceration and sequelae. Recurrence occurs more often in females and segmental hemangiomas. Segmental infantile hemangioma and PHACES syndrome require a longer time of treatment. Specific protocols are required for infantile hemangiomas with a high risk of recurrence.

摘要

背景

婴儿血管瘤(IH)在儿科人群中的发病率约为 4%至 10%。识别临床亚型和预示并发症风险增加的情况对于治疗成功至关重要。

目的

确定并发症、复发和不美观后遗症的危险因素。

方法

回顾性队列研究了 2006 年至 2018 年期间在阿雷格里港联邦大学健康科学皮肤科接受随访的患有婴儿血管瘤的患者。

结果

共纳入 190 例患者;24%存在某种类型的并发症,其中溃疡最常见,86%需要治疗。相关性分析显示,溃疡与混合性 IH(p=0.004)、节段性 IH(p<0.01)和臀部位置(p=0.001)有统计学关系。普萘洛尔治疗的平均时间为 12.7 个月。患有 PHACES 综合征和节段性婴儿血管瘤的患者需要更长的治疗时间(p<0.001 和 p=0.0407),以及在 5 个月后开始治疗的患者(p<0.0001)。接受治疗的患者中有 16.6%(均为女性)出现复发,所有患者均位于头颈部(主要在上眼睑、Cyrano、S3 节段,伴有腮腺受累);94%;94%为混合性和深部亚型,分别为 61%和 38.8%。大约 1/3 的患者存在一些不美观的后遗症。

研究局限性

由于这是一项回顾性研究,一些患者的数据和照片丢失。

结论

混合性和节段性血管瘤是溃疡和后遗症的危险因素。复发更多发生在女性和节段性血管瘤中。节段性婴儿血管瘤和 PHACES 综合征需要更长的治疗时间。对于复发风险高的婴儿血管瘤,需要制定特定的方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/05bddf647ba0/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/ec960eac0bcc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/c3254fc9fe8d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/24e1f3601435/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/d4ac77731808/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/05bddf647ba0/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/ec960eac0bcc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/c3254fc9fe8d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/24e1f3601435/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/d4ac77731808/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7ea/8799848/05bddf647ba0/gr5.jpg

相似文献

1
Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae.婴幼儿血管瘤:并发症、复发和不美观后遗症的风险因素。
An Bras Dermatol. 2022 Jan-Feb;97(1):37-44. doi: 10.1016/j.abd.2021.05.009. Epub 2021 Nov 27.
2
Predictors of poor response to oral propranolol in infantile hemangiomas.婴儿血管瘤口服普萘洛尔治疗反应不佳的预测因素。
Arch Pediatr. 2023 Oct;30(7):455-457. doi: 10.1016/j.arcped.2023.06.004. Epub 2023 Jun 30.
3
Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.声门下血管瘤:了解其与胡须分布区域面部节段性血管瘤的关联。
Int J Pediatr Otorhinolaryngol. 2018 Oct;113:34-37. doi: 10.1016/j.ijporl.2018.07.019. Epub 2018 Jul 12.
4
Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.普萘洛尔治疗婴儿血管瘤的疗效和安全性:99 例报告。
Dermatology. 2014;228(2):136-44. doi: 10.1159/000351557. Epub 2014 Feb 15.
5
[Infantile hemangiomas: the revolution of beta-blockers].[婴儿血管瘤:β受体阻滞剂的变革]
Rev Prat. 2014 Dec;64(10):1421-8.
6
Propranolol for infantile hemangiomas.普萘洛尔用于治疗婴儿血管瘤。
Pediatr Dermatol. 2011 Mar-Apr;28(2):108-14. doi: 10.1111/j.1525-1470.2011.01345.x. Epub 2011 Mar 8.
7
Recurrence rate of infantile hemangioma after oral propranolol therapy.婴幼儿血管瘤口服普萘洛尔治疗后的复发率。
Eur J Pediatr. 2021 Feb;180(2):585-590. doi: 10.1007/s00431-020-03872-5. Epub 2020 Nov 13.
8
Management of infantile hemangiomas-experience of a tertiary hospital.婴儿血管瘤的管理——一家三级医院的经验
Eur J Pediatr. 2023 Apr;182(4):1611-1618. doi: 10.1007/s00431-023-04827-2. Epub 2023 Jan 27.
9
Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.口服普萘洛尔治疗腮腺部血管瘤:与其他婴幼儿血管瘤的回顾性比较。
Head Neck. 2021 May;43(5):1553-1562. doi: 10.1002/hed.26625. Epub 2021 Feb 4.
10
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment.脉冲染料激光联合口服普萘洛尔治疗后婴儿血管瘤的持续生长。
J Dermatol. 2018 Sep;45(9):1109-1112. doi: 10.1111/1346-8138.14517. Epub 2018 Jun 28.

引用本文的文献

1
A Multimodal Approach to a Complex PHACES Patient With Progressive Infantile Hemangioma: A Case Report and Review of Literature.一种针对患有进行性婴儿血管瘤的复杂PHACES患者的多模态治疗方法:病例报告及文献综述
Cureus. 2025 Mar 8;17(3):e80261. doi: 10.7759/cureus.80261. eCollection 2025 Mar.
2
Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China.普萘洛尔片与口服液治疗重症婴儿血管瘤新生儿的疗效与安全性:一项中国的回顾性研究
Sci Rep. 2025 Jan 2;15(1):459. doi: 10.1038/s41598-024-84653-0.
3
Our Experience in Treating Infantile Hemangioma: Prognostic Factors for Relapse After Propranolol Discontinuation.

本文引用的文献

1
Clinical Practice Guideline for the Management of Infantile Hemangiomas.婴幼儿血管瘤管理临床实践指南。
Pediatrics. 2019 Jan;143(1). doi: 10.1542/peds.2018-3475.
2
Late growth of infantile hemangiomas in children >3 years of age: A retrospective study.儿童 >3 岁时婴幼儿血管瘤的迟发性生长:一项回顾性研究。
J Am Acad Dermatol. 2019 Feb;80(2):493-499. doi: 10.1016/j.jaad.2018.07.061. Epub 2018 Oct 5.
3
Infantile hemangiomas: a 7-year experience of a single-center.婴儿血管瘤:单中心7年经验
我们治疗婴儿血管瘤的经验:普萘洛尔停药后复发的预后因素
Adv Ther. 2025 Jan;42(1):537-547. doi: 10.1007/s12325-024-03017-2. Epub 2024 Nov 26.
4
Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway.通过SOX4靶向ESM1可通过PI3K/AKT信号通路促进婴幼儿血管瘤的进展。
Precis Clin Med. 2024 Oct 9;7(4):pbae026. doi: 10.1093/pcmedi/pbae026. eCollection 2024 Dec.
5
Infantile Hemangiomas of the Head and Neck: A Single-Center Experience.头颈部婴幼儿血管瘤:单中心经验
Children (Basel). 2024 Mar 6;11(3):311. doi: 10.3390/children11030311.
Clujul Med. 2017;90(4):396-400. doi: 10.15386/cjmed-781. Epub 2017 Oct 20.
4
Infantile haemangioma.婴儿血管瘤。
Lancet. 2017 Jul 1;390(10089):85-94. doi: 10.1016/S0140-6736(16)00645-0. Epub 2017 Jan 13.
5
Rebound Growth of Infantile Hemangiomas After Propranolol Therapy.普萘洛尔治疗后婴儿血管瘤的反弹生长
Pediatrics. 2016 Apr;137(4). doi: 10.1542/peds.2015-1754. Epub 2016 Mar 7.
6
Increasing incidence of infantile hemangiomas (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weight.过去35年中婴儿血管瘤(IH)发病率的上升:与出生时孕周和出生体重下降的相关性。
J Am Acad Dermatol. 2016 Jan;74(1):120-6. doi: 10.1016/j.jaad.2015.08.024. Epub 2015 Oct 19.
7
Diagnosis and Management of Infantile Hemangioma.婴幼儿血管瘤的诊断与治疗。
Pediatrics. 2015 Oct;136(4):e1060-104. doi: 10.1542/peds.2015-2485.
8
Diagnosis and management of infantile hemangiomas.婴幼儿血管瘤的诊断与治疗。
Pediatr Clin North Am. 2014 Apr;61(2):383-402. doi: 10.1016/j.pcl.2013.11.010. Epub 2014 Feb 18.
9
Late rebound of infantile hemangioma after cessation of oral propranolol.口服普萘洛尔停药后婴儿血管瘤的晚期复发
Pediatr Dermatol. 2013 Sep-Oct;30(5):587-91. doi: 10.1111/pde.12190.
10
Haemangioma: clinical course, complications and management.血管瘤:临床过程、并发症及处理。
Br J Dermatol. 2013 Jul;169(1):20-30. doi: 10.1111/bjd.12436.